


Dobutamine hydrochloride

| | |
|---------------------------|--|
| Cat. No.: | HY-15746 |
| CAS No.: | 49745-95-1 |
| Molecular Formula: | C ₁₈ H ₂₄ ClNO ₃ |
| Molecular Weight: | 337.84 |
| Target: | Adrenergic Receptor |
| Pathway: | GPCR/G Protein; Neuronal Signaling |
| Storage: | 4°C, sealed storage, away from moisture * In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture) |



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 33 mg/mL (97.68 mM)
 H₂O : 20 mg/mL (59.20 mM; Need ultrasonic)
 * "≥" means soluble, but saturation unknown.

| Preparing Stock Solutions | Solvent Concentration | Mass | 1 mg | 5 mg | 10 mg |
|---------------------------|-----------------------|------|-----------|------------|------------|
| | | | | | |
| | 1 mM | | 2.9600 mL | 14.7999 mL | 29.5998 mL |
| | 5 mM | | 0.5920 mL | 2.9600 mL | 5.9200 mL |
| | 10 mM | | 0.2960 mL | 1.4800 mL | 2.9600 mL |

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: PBS
Solubility: 16.67 mg/mL (49.34 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (7.40 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (7.40 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (7.40 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Dobutamine hydrochloride is a synthetic catecholamine that acts on α1-AR, β1-AR, β2-AR (α-1, β-1 and β-2 adrenoceptors). Dobutamine hydrochloride is a selective β1-AR agonist, relatively weak activity at α1-AR and β2-AR. Dobutamine hydrochloride can increase cardiac output and correct hypoperfusion^{[1][2][3][4]}.

IC₅₀ & Target

α adrenergic receptor β adrenergic receptor

In Vivo

Dobutamine hydrochloride has a rapid onset of action and a short half-life [2].

?Dobutamine hydrochloride (0.15-20 mg/kg; i.p.) results in subsequent increase in the left ventricular function and heart rate acceleration with an increasing dose in wildtype mice[3].

?Dobutamine hydrochloride results in significant inotropic, lusitropic, and chronotropic cardiac response with a high dose in wildtype mice[3].

?Low doses of Dobutamine hydrochloride significantly increases inotropic and lusitropic cardiac performance without chronotropic changes in the Tgαq*44 mice[3].

?Dobutamine hydrochloride increases heart rate only after high doses, but then inotropic and lusitropic cardiac functional reserve is lost[3].

?Dobutamine hydrochloride increases alveolar liquid clearance in ventilated rats by beta-2 receptor stimulation[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

| | |
|-----------------|--|
| Animal Model: | Tgαq*44 mice (heart failure models)[3] |
| Dosage: | 0.15 mg/kg, 0.5 mg/kg as a low dose, 1.5 mg/kg, 5 mg/kg, 20 mg/kg as a high dose |
| Administration: | Intraperitoneal injection |
| Result: | Induced different response in cardiac function on a low and high dose in mice with with heart failure. |

CUSTOMER VALIDATION

- Comput Struct Biotechnol J. 2023 Jul 7, 21, 3490-3502.
- Front Cell Dev Biol. 2022 Apr 20;10:889656.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Tuttle RR, et al. Dobutamine: development of a new catecholamine to selectively increase cardiac contractility. *Circ Res.* 1975 Jan;36(1):185-96.
- [2]. Vallet B, et al. Dobutamine: mechanisms of action and use in acute cardiovascular pathology. *Ann Cardiol Angeiol (Paris).* 1991 Jun;40(6):397-402.
- [3]. Tyrankiewicz U, et al. Characterization of the cardiac response to a low and high dose of dobutamine in the mouse model of dilated cardiomyopathy by MRI in vivo. *J Magn Reson Imaging.* 2013 Mar;37(3):669-77.
- [4]. Tibayan FA, et al. Dobutamine increases alveolar liquid clearance in ventilated rats by beta-2 receptor stimulation. *Am J Respir Crit Care Med.* 1997 Aug;156(2 Pt 1):438-44.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA